The effect of varenicline on heart rate variability in healthy smokers and nonsmokers

Arı, Hasan; Celiloğlu, Nuran; Arı, Selma; Coşar, Selvi; Doganay, K.; Bozat, Tahsin

doi:10.1016/j.autneu.2011.05.005

Cited by 9 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 Activity at these subunits may contribute to the CV effects of this drug through parasympathetic and sympathetic stimulation of cardiac neurons, leading to changes in BP, heart rate, cardiac contractility, and myocardial ischemia. 11,45,46 …”

Section: Vareniclinementioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular effects of pharmacologic therapies for smoking cessation

Sobieraj

White²,

Baker

2013

Journal of the American Society of Hypertension

View full text Add to dashboard Cite

Tobacco dependence is a potent risk factor for cardiovascular (CV) diseases and despite known harms of smoking and benefits associated with smoking cessation, approximately 20% of the adult population with CV diseases or hypertension continue to smoke. Extensive research has demonstrated that nicotine replacement, varenicline, and bupropion sustained-release are superior to placebo for short- and intermediate-term smoking cessation. Due to their mechanisms of action, some smoking cessation therapies have been thought to have the potential to increase CV risk, particularly if the pharmacotherapies are taken while individuals are still smoking. Hence, we have analytically reviewed the literature describing the CV effects of therapies for smoking cessation, particularly as they apply to patients with CV disease.

show abstract

Section: Vareniclinementioning

confidence: 99%

“…45 Thirty healthy subjects (15 smokers and 15 non-smokers) were randomly assigned to receive a single dose of varenicline 2 mg or placebo. Varenicline did not impact any of the variables in the group of smokers (p>0.05 for all); in non-smokers there was an increase in sympathetic activity following the dose of varenicline.…”

Section: Vareniclinementioning

confidence: 99%

Cardiovascular effects of pharmacologic therapies for smoking cessation

Sobieraj

White²,

Baker

2013

Journal of the American Society of Hypertension

View full text Add to dashboard Cite

show abstract

“…However, the arrhythmogenic potential of varenicline has not been fully investigated. While single-dose varenicline has been reported to cause no change in heart rate variability in healthy smokers, it has increased the low frequency/high frequency ratio in healthy nonsmokers, which indicates increased sympathetic tonus (26). The elimination half-life of varenicline is approximately 24 h (27) and the peak concentration is reached in 3 h to 4 h after oral administration.…”

Section: Discussionmentioning

confidence: 98%

Short-term effects of varenicline therapy on homogeneity of heart rate, atrioventricular conduction and ventricular repolarization

KaraveliogAAlu¹,

Karapınar²

2015

Curr Res Cardiol

View full text Add to dashboard Cite

69Y Karavelioğlu, H Karapınar, M Kalçık, Z Küçükdurmaz, S Özkurt, T Sarak. Short-term effects of varenicline therapy on homogeneity of heart rate, atrioventricular conduction and ventricular repolarization. Curr Res Cardiol 2015;2(2):69-72.BaCKgRound: The effects of varenicline, an effective drug for smoking cessation, on atrioventricular and ventricular conductance remain unknown. oBjeCTive: To evaluate the effects of varenicline on heart rate, PR interval, QT interval and QT dispersion (QTd). MeTHodS: A total of 60 smokers were prospectively enrolled in the present study. Twelve-lead electrocardiogram recordings were obtained for all subjects before and on the 15th day of drug administration. Electrocardiograms were recorded at an amplitude of 20 mm/mV and a sweep speed of 50 mm/s. ReSulTS:The mean (± SD) age of the volunteers was 38±10 years. Thirtyfour (57%) were male. Fourteen (23%) had hypertension, eight (13%) had diabetes and six (10%) had chronic obstructive pulmonary disease. The mean heart rate was 74.7±13.3 beats/min, and mean systolic and diastolic blood pressures on admission were 122.3±14.3 mmHg and 76.5±10.2 mmHg, respectively. Heart rate, and systolic and diastolic blood pressures did not change with varenicline treatment. Varenicline treatment resulted in limited prolongation in PR interval, which appropached significance (163.5±18.3 ms versus 168.2±17.9 ms; P=0.053), while RR interval (796.3±117.4 ms versus 798.3±123.7 ms; P=0.926), QT interval (384.1±17.5 ms versus 383.4±20.9 ms; P=0.852) and QTd (52.6±14.9 ms versus 52.2±14.9 ms; P=0.919) were not significantly changed. ConCluSion: Varenicline had a limited effect on atrioventricular conduction, while it had no effect on heart rate, QT interval and QTd. Further studies are needed to prove the effects of varenicline on the conduction system of the heart, especially on PR interval.

show abstract

“…Varenicline has been shown to be more effective for smoking cessation than bupropion and to be at least as effective as NRT [50]. However, due to its alpha 7-subunit agonist and partial agonist activity at alpha-3-beta-4-subunit of nicotine acetylcholine receptors, it is associated with increased parasympathetic and sympathetic stimulation of cardiac neurons and in turn associated with changes in heart rate, blood pressure, myocardial contractility, and ischemia [51][52][53]. An association between varenicline and CVD events could be due to modulation of parasympathetic output, catecholamine release, or a possible prothrombotic effect [54][55][56].…”

Section: Vareniclinementioning

confidence: 98%

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

et al. 2014

View full text Add to dashboard Cite

Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.

show abstract

The effect of varenicline on heart rate variability in healthy smokers and nonsmokers

Cited by 9 publications

References 21 publications

Cardiovascular effects of pharmacologic therapies for smoking cessation

Cardiovascular effects of pharmacologic therapies for smoking cessation

Short-term effects of varenicline therapy on homogeneity of heart rate, atrioventricular conduction and ventricular repolarization

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

Contact Info

Product

Resources

About